$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000153217615000008 Filed on February 12, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$610.4M	$597.0M	$457.6M
YoY Change	47.23%	39.59%	50.34%
Cost Of Revenue	$48.10M	$28.25M	$27.28M
YoY Change	59.27%	40.25%	24.91%
Gross Profit	$562.3M	$568.8M	$430.4M
YoY Change	46.28%	39.56%	52.31%
Gross Profit Margin	92.12%	95.27%	94.04%
Selling, General & Admin	$82.10M	$97.61M	$72.46M
YoY Change	42.29%	108.19%	51.9%
% of Gross Profit	14.6%	17.16%	16.84%
Research & Development	$268.1M	$224.0M	$187.5M
YoY Change	48.12%	41.54%	27.2%
% of Gross Profit	47.68%	39.39%	43.56%
Depreciation & Amortization	$11.30M	$10.80M	$9.700M
YoY Change	16.49%	14.89%	3.19%
% of Gross Profit	2.01%	1.9%	2.25%
Operating Expenses	$350.2M	$321.7M	$259.9M
YoY Change	46.71%	56.77%	33.24%
Operating Profit	$212.1M	$236.8M	$158.1M
YoY Change	45.57%	17.02%	80.73%
Interest Expense	-$11.70M	$11.74M	$11.37M
YoY Change	1.74%	2.83%	1.15%
% of Operating Profit	-5.52%	4.96%	7.19%
Other Income/Expense, Net	-$2.300M	-$11.12M	-$10.41M
YoY Change	-675.0%	2.04%	-3.02%
Pretax Income	$198.2M	$225.7M	$147.7M
YoY Change	47.25%	17.87%	92.45%
Income Tax	$101.3M	$84.38M	$60.32M
% Of Pretax Income	51.11%	37.39%	40.84%
Net Earnings	$96.81M	$141.3M	$87.38M
YoY Change	-79.42%	-26.2%	13.86%
Net Earnings / Revenue	15.86%	23.67%	19.09%
Basic Earnings Per Share	$0.98	$1.44	$0.89
Diluted Earnings Per Share	$0.86	$1.25	$0.79
COMMON SHARES
Basic Shares Outstanding		98.23M shares	97.70M shares
Diluted Shares Outstanding		116.7M shares	111.1M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$694.0M	$445.0M	$538.0M
YoY Change	125.32%	69.2%	78.74%
Cash & Equivalents	$535.6M	$263.2M	$381.7M
Short-Term Investments	$158.0M	$182.0M	$156.0M
Other Short-Term Assets	$89.00M	$144.0M	$98.00M
YoY Change	-51.37%	161.82%	1125.0%
Inventory	$70.35M	$63.29M	$57.16M
Prepaid Expenses
Receivables	$787.1M	$855.8M	$767.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.797B	$1.634B	$1.561B
YoY Change	49.0%	72.27%	103.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$527.0M	$453.9M	$419.7M
YoY Change	38.7%	21.71%	12.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$390.0M	$330.0M	$173.0M
YoY Change	43.91%	5.43%	-39.93%
Other Assets	$5.327M	$4.409M	$15.21M
YoY Change	-76.94%	-75.94%	-45.68%
Total Long-Term Assets	$1.154B	$1.006B	$816.9M
YoY Change	31.97%	41.33%	18.56%
TOTAL ASSETS
Total Short-Term Assets	$1.797B	$1.634B	$1.561B
Total Long-Term Assets	$1.154B	$1.006B	$816.9M
Total Assets	$2.951B	$2.640B	$2.378B
YoY Change	41.84%	59.0%	63.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$62.00M	$31.00M	$24.00M
YoY Change	58.97%	40.91%	-7.69%
Accrued Expenses	$189.0M	$188.0M	$129.0M
YoY Change	162.5%	84.31%	27.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$298.8M	$268.7M	$203.8M
YoY Change	82.72%	50.49%	11.37%
LONG-TERM LIABILITIES
Long-Term Debt	$505.0M	$481.0M	$473.0M
YoY Change	10.75%	6.89%	6.29%
Other Long-Term Liabilities	$11.33M	$10.57M	$10.20M
YoY Change	56.08%	51.32%	-95.66%
Total Long-Term Liabilities	$11.33M	$10.57M	$10.20M
YoY Change	56.08%	51.32%	-98.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$298.8M	$268.7M	$203.8M
Total Long-Term Liabilities	$11.33M	$10.57M	$10.20M
Total Liabilities	$998.9M	$950.2M	$884.9M
YoY Change	19.62%	11.19%	2.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$92.69M	-$189.5M	-$330.8M
YoY Change	-82.07%	-80.81%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares	0.000 shares
Shareholders Equity	$1.965B	$1.690B	$1.493B
YoY Change
Total Liabilities & Shareholders Equity	$2.951B	$2.640B	$2.378B
YoY Change	41.84%	59.0%	63.12%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	$96.81M	$141.3M	$87.38M
YoY Change	-79.42%	-26.2%	13.86%
Depreciation, Depletion And Amortization	$11.30M	$10.80M	$9.700M
YoY Change	16.49%	14.89%	3.19%
Cash From Operating Activities	$276.7M	$92.50M	$128.2M
YoY Change	196.89%	-3954.17%	-263.52%
INVESTING ACTIVITIES
Capital Expenditures	-$69.00M	-$31.60M	-$34.50M
YoY Change	356.95%	206.8%	169.53%
Acquisitions
YoY Change
Other Investing Activities	-$40.90M	-$182.8M	$151.1M
YoY Change	-138.48%	374.81%	-219.64%
Cash From Investing Activities	-$110.0M	-$214.4M	$116.6M
YoY Change	-220.75%	339.34%	-183.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	105.5M	3.600M	-43.50M
YoY Change	-244.52%	-300.0%	770.0%
NET CHANGE
Cash From Operating Activities	276.7M	92.50M	128.2M
Cash From Investing Activities	-110.0M	-214.4M	116.6M
Cash From Financing Activities	105.5M	3.600M	-43.50M
Net Change In Cash	272.2M	-118.3M	201.3M
YoY Change	144.56%	123.21%	-190.43%
FREE CASH FLOW
Cash From Operating Activities	$276.7M	$92.50M	$128.2M
Capital Expenditures	-$69.00M	-$31.60M	-$34.50M
Free Cash Flow	$345.7M	$124.1M	$162.7M
YoY Change	219.21%	1470.89%	-348.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	27323000000	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	8600000	USD
CY2013Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	16100000	USD
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2013Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	23654000	USD
CY2014Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	41555000	USD
CY2013Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	66855000	USD
CY2014Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	133085000	USD
CY2012	regn	Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation	50466000	USD
CY2013	regn	Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation Adjustmentsrelatedtotaxwithholdingforrestrictedsharebasedcompensation	15664000	USD
CY2014	regn	Branded Prescription Drug Fee BrandedPrescriptionDrugFee	40600000	USD
CY2012	regn	Costofmanufacturing Costofmanufacturing	528000	USD
CY2013	regn	Costofmanufacturing Costofmanufacturing	37307000	USD
CY2014	regn	Costofmanufacturing Costofmanufacturing	75988000	USD
CY2014	regn	Debt Conversion DebtConversion	230600000	USD
CY2013Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	34185000	USD
CY2014Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	58098000	USD
CY2013Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	107677000	USD
CY2014Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	103909000	USD
CY2013Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	12815000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	15927000	USD
CY2013Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	76522000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	72367000	USD
CY2013Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	18942000	USD
CY2014Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	12908000	USD
CY2013Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	184258000	USD
CY2014Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	310938000	USD
CY2012	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	715000	shares
CY2013	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	433000	shares
CY2014	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	425000	shares
CY2012	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16000000	USD
CY2013	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	16200000	USD
CY2014	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	14500000	USD
CY2014	regn	Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million	100000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million	200000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived	500000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million	600000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million	700000000	USD
CY2014Q3	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million	800000000	USD
CY2014Q3	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million	900000000	USD
CY2014Q4	regn	Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentswerereceived1billion Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentswerereceived1billion	1000000000	USD
CY2014Q4	regn	Limitpricepershareforwarrantholderstocloseouthedgeposition Limitpricepershareforwarrantholderstocloseouthedgeposition	397.75
CY2014	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	-148496000	USD
CY2013Q4	regn	Maximumnumberofsharesissuableuponexerciseofwarrants Maximumnumberofsharesissuableuponexerciseofwarrants	4760840	shares
CY2014Q4	regn	Maximumnumberofsharesissuableuponexerciseofwarrants Maximumnumberofsharesissuableuponexerciseofwarrants	3540095	shares
CY2014Q4	regn	Maximumreductionofwarrantsheldbywarrantholder Maximumreductionofwarrantsheldbywarrantholder	493229	shares
CY2014	regn	Numberofdemandrightstorequirethe Companytoconductregisteredunderwrittenpublicoffering NumberofdemandrightstorequiretheCompanytoconductregisteredunderwrittenpublicoffering	3
CY2014	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	6
CY2014	regn	Numberoftherapeuticantibodiescurrentlyunderdevelopment Numberoftherapeuticantibodiescurrentlyunderdevelopment	5
CY2012	regn	Other Collaboration Revenue OtherCollaborationRevenue	70099000	USD
CY2013	regn	Other Collaboration Revenue OtherCollaborationRevenue	220289000	USD
CY2014	regn	Other Collaboration Revenue OtherCollaborationRevenue	495555000	USD
CY2014Q4	regn	Percentage Of Prompt Pay Discount Company Accrues PercentageOfPromptPayDiscountCompanyAccrues	1
CY2014	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2012	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	10900000	USD
CY2013	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	11500000	USD
CY2014	regn	Rent Charges For Utilities Real Estate Taxes And Operating Expense RentChargesForUtilitiesRealEstateTaxesAndOperatingExpense	13600000	USD
CY2013Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	63189000	USD
CY2014Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	156962000	USD
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	250896000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	484228000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	61936000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	99508000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	787071000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	739379000	USD
CY2013Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	104707000	USD
CY2014Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	121058000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	221617000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	253984000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1188000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	52251000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2045857000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2404118000	USD
CY2012	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	4308000	USD
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	216857000	USD
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	448556000	USD
CY2012	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	112834000	USD
CY2013	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	179423000	USD
CY2014	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2011Q4	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	120600000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	691869000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-294552000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94181000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	200101000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	312303000	USD
CY2012	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-824884000	USD
CY2013	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	159286000	USD
CY2014	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	395083000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2013Q4	us-gaap	Assets Assets	2951013000	USD
CY2014Q4	us-gaap	Assets Assets	3871827000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	1796934000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2167461000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	548267000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	711915000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	548322000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	631477000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	0	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses	0	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	447000	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	1551000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	239812000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	426941000	USD
CY2013	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	447000	USD
CY2014	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses	1551000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	239812000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	426941000	USD
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4138000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1128000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	383410000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	360208000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	1177000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	158376000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	251761000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	547101000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	613097000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1000000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	1200000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	392000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	81989000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	447000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	1551000	USD
CY2013Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	343363000	USD
CY2014Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	398981000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	286550000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	18107000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	19728000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	19307000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	18897000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	18497000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	192014000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	483610000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230276000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-253334000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	305332000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	113111000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	750965000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	424340000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	401513000	USD
CY2013Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	142370000	USD
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	472231000	USD
CY2013Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	320315000	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	146773000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	83927000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	118048000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	129030000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	920764000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	1344717000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	1981126000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	201475000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	447370000	USD
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	433000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2879000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4308000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	225397000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	478967000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4308000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	23489000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28718000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-300319000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	54910000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-68700000	USD
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-9000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1485000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-340156000	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	63601000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-51294000	USD
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	929000	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32016000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	47000000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	74025000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	184199000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	176276000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-39837000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	8700000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	18891000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	88033000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	75503000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	279314000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	348479000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	276555000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	316104000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	44677000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	49235000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	231878000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	266869000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	277484000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	348120000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	135000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	150000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	34215000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	41252000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	18902000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	8078000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9372000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16099000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	109715000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	194489000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1830000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	359000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	28186000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	929000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3034000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	252000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3578000	USD
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6300000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5700000	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	13100000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36940000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41204000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52686000	USD
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.92
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.33
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.92
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.46
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.75
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.90
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.81
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.58
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.70
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.07
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.811
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.405
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.551
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.390
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.054
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.028
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.027
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.049
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.153
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.010
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37767000	USD
CY2012	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	990000	shares
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.022
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.093
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.054
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Domestic EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies Domestic EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic	0.025
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.049
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.074
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	69429000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	92778000	USD
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4308000	USD
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	216857000	USD
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	448556000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1200000	USD
CY2013Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	44186000	USD
CY2014Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	58655000	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-33469000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	414421000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	713360000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	775747000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-335848000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288998000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	427673000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	340200000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	34000000	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1057000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	59847000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10979000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	136684000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	162236000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	588398000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	258994000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	62432000	USD
CY2012	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	340156000	USD
CY2013	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-63601000	USD
CY2014	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	66604000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-41077000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-27974000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	19102000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28932000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	47956000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60900000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	25371000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7571000	USD
CY2013Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	389891000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2707000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2936000	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	4761000	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	14231000	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10233000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9440000	shares
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	USD
CY2013	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	1900000	USD
CY2014	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6200000	USD
CY2012	us-gaap	Interest Expense InterestExpense	45304000	USD
CY2013	us-gaap	Interest Expense InterestExpense	46437000	USD
CY2014	us-gaap	Interest Expense InterestExpense	37372000	USD
CY2012	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	29126000	USD
CY2013	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2014	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	21946000	USD
CY2013	us-gaap	Interest Paid Net InterestPaidNet	23842000	USD
CY2014	us-gaap	Interest Paid Net InterestPaidNet	20614000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14352000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10768000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	70354000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	128861000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9120000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10923000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	35868000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	73519000	USD
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	17000000	USD
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	9100000	USD
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	6000000	USD
CY2013Q4	us-gaap	Land Land	2768000	USD
CY2014Q4	us-gaap	Land Land	2768000	USD
CY2013Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	26370000	USD
CY2014Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	42600000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	998937000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1329502000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2951013000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3871827000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	298835000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	654660000	USD
CY2012	us-gaap	Licenses Revenue LicensesRevenue	26471000	USD
CY2013	us-gaap	Licenses Revenue LicensesRevenue	28506000	USD
CY2014	us-gaap	Licenses Revenue LicensesRevenue	31941000	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	158376000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	251761000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2014	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	27100000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	696000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	460154000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-97646000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77139000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-209269000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81073000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-355455000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420777000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-74615000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	583648000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	743157000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	750269000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	98874000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	87376000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	141306000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	96806000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	424362000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	65443000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	92735000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	79720000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	110176000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	348074000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	779395000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	424362000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	348074000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43292000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-46668000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-62684000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	7500000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	457713000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	760028000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	838431000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	108622000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	10819000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9957000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	9779000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	9605000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	10191000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	58271000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	8029000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	9875000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14312000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29022000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	117302000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5327000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53439000	USD
CY2013Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	11014000	USD
CY2014Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	33651000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	939000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	96407000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11330000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40855000	USD
CY2012	us-gaap	Other Noncash Expense OtherNoncashExpense	22925000	USD
CY2013	us-gaap	Other Noncash Expense OtherNoncashExpense	23061000	USD
CY2014	us-gaap	Other Noncash Expense OtherNoncashExpense	18052000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-34049000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23690000	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-30003000	USD
CY2012	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2012000	USD
CY2013	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-231000	USD
CY2014	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8157000	USD
CY2012	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	294552000	USD
CY2012	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163300000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	195087000	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	470945000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	577278000	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	564188000	USD
CY2012	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	49337000	USD
CY2013	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	156323000	USD
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	333006000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32952000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	71486000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	63549000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	57393000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126045000	USD
CY2011Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	93800000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	439209000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	378146000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	476417000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	748600000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1228293000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	526983000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974309000	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2012	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2013	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	220639000	USD
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2203000	USD
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	2024000	USD
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1095000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	625554000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859947000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1271353000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92692000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	255382000	USD
CY2012	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	423814000	USD
CY2013	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	430111000	USD
CY2014	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	541299000	USD
CY2013Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	45000000	USD
CY2013Q4	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	25000000	USD
CY2014Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	30000000	USD
CY2014Q2	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	15000000	USD
CY2014Q3	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	30000000	USD
CY2014Q4	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	30000000	USD
CY2012	us-gaap	Revenues Revenues	1378477000	USD
CY2013Q1	us-gaap	Revenues Revenues	439664000	USD
CY2013Q2	us-gaap	Revenues Revenues	457642000	USD
CY2013Q3	us-gaap	Revenues Revenues	597027000	USD
CY2013Q4	us-gaap	Revenues Revenues	610412000	USD
CY2013	us-gaap	Revenues Revenues	2104745000	USD
CY2014Q1	us-gaap	Revenues Revenues	625740000	USD
CY2014Q2	us-gaap	Revenues Revenues	665700000	USD
CY2014Q3	us-gaap	Revenues Revenues	725788000	USD
CY2014Q4	us-gaap	Revenues Revenues	802329000	USD
CY2014	us-gaap	Revenues Revenues	2819557000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	858093000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1425839000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1750762000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	210755000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	329415000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	504755000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	94157000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	198399000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	307238000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	691356000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6325000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	5718000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	13125000	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	67174000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54762000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125897000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	485732000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1245385000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	1952076000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2542325000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2017732	shares
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	-169530000	USD
CY2014	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5596000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11274000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26627000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	57615000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	572000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3014000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1873000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7620000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	27538000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3805000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	8305000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	6464000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8400000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	23500000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	51200000	USD
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2218000	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	18826000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	62251000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	89875000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	111855000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	45643000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	84100000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	111675000	USD
CY2012	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20697000	shares
CY2013	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	13373000	shares
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12801000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115382000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111290000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113413000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94685000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97917000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100612000	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. A large portion of the Company's cash is held by a few major financial institutions. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are significant. Accounts receivable from product sales of EYLEA and ARCALYST are due from several distributors and specialty pharmacies, who are the Company's customers. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> and 2013, one individual customer accounted for </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">, respectively, of the Company's net trade accounts receivable balances. The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. As of December 31, 2014 and 2013, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves against trade accounts receivable. In addition, during the years ended December 31, 2014, 2013, and 2012, the Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t recognize any charges for write-offs of trade accounts receivable. </font></div></div>
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regeneron Pharmaceuticals, Inc. and its subsidiaries (collectively, the "Company" or "Regeneron") is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company has product candidates in development in areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The Company is a party to collaboration agreements to develop certain of these product candidates (see Note 4). The Company also currently has three marketed products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">EYLEA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> (aflibercept) Injection</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">known in the scientific literature as VEGF Trap-Eye, which is available in the United States, European Union ("EU"), Japan, and certain other countries outside the United States for the treatment of neovascular age-related macular degeneration ("wet AMD"), macular edema following central retinal vein occlusion ("CRVO"), and diabetic macular edema ("DME"). In addition, EYLEA for the treatment of macular edema following retinal vein occlusion ("RVO"), which includes macular edema following branch retinal vein occlusion ("BRVO"), is available in the United States, and EYLEA for the treatment of myopic choroidal neovascularization ("mCNV") is available in Japan. Bayer HealthCare has additional regulatory applications for various indications pending in other countries. The Company is collaborating with Bayer HealthCare on the global development and commercialization of EYLEA outside the United States. The Company maintains exclusive rights to EYLEA in the United States and is entitled to all profits from such sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ZALTRAP</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> (ziv-aflibercept) Injection for Intravenous Infusion, known in the scientific literature as VEGF Trap</font><font style="font-family:inherit;font-size:10pt;">, which is available in the United States, EU, and certain other countries for treatment, in combination with 5-fluorouracil, leucovorin, irinotecan ("FOLFIRI"), for patients with metastatic colorectal cancer ("mCRC") that is resistant to or has progressed following an oxaliplatin-containing regimen. Regeneron and Sanofi globally collaborate on the development and commercialization of ZALTRAP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ARCALYST</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> (rilonacept) Injection for Subcutaneous Use</font><font style="font-family:inherit;font-size:10pt;">, which is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes ("CAPS"), including Familial Cold Auto-inflammatory Syndrome ("FCAS") and Muckle-Wells Syndrome ("MWS"), in adults and children 12 and older. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one business segment, which includes all activities related to the discovery, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Company's business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, product development, obtaining regulatory approvals, market acceptance, competition, and obtaining and enforcing patents.</font></div></div>
CY2014	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. </font></div></div>
CY2014	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to several distributors and specialty pharmacies. The Company sells ARCALYST in the United States to two specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services ("PHS"), and other institutions (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Pay Discounts: </font><font style="font-family:inherit;font-size:10pt;"> No prompt pay discounts are currently offered to the Company's customers on sales of EYLEA. In connection with sales of ARCALYST, the Company offers discounts to its customers for prompt payments. The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount. Therefore, the Company accrues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the prompt pay discount that is based on the gross amount of each ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">invoice, at the time of sale.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div></div>
CY2014	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></font><font style="font-family:inherit;font-size:10pt;">Technology Licensing</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune</font><font style="font-family:inherit;font-size:10pt;"> technology in its internal research programs. The terms of these agreements may include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company's </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">VelocImmune </font><font style="font-family:inherit;font-size:10pt;">technology. Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include provisions related to product sales, such as rebates, chargebacks, and distribution-related fees; periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements; periods over which certain clinical trial costs are recognized; fair value of stock options; inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value; capitalization of inventory costs associated with the Company's products prior to regulatory approval; deferred tax asset valuation allowance; and the assessment of uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer HealthCare:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of ZALTRAP and commercialization of antibodies, which are provided by Sanofi, and include an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer HealthCare collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer HealthCare, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of development expenses incurred by its collaborators, Bayer HealthCare and Sanofi, including the Company's share of Bayer HealthCare and Sanofi estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent period are adjusted, if necessary, in the subsequent period to reflect actual amounts.</font></div></div>

Files In Submission

Name	View Source	Status
0001532176-15-000008-index-headers.html	Edgar Link	pending
0001532176-15-000008-index.html	Edgar Link	pending
0001532176-15-000008.txt	Edgar Link	pending
0001532176-15-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123114x10k.htm	Edgar Link	pending
regn-123114_chartx06558.jpg	Edgar Link	pending
regn-20141231.xml	Edgar Link	completed
regn-20141231.xsd	Edgar Link	pending
regn-20141231_cal.xml	Edgar Link	unprocessable
regn-20141231_def.xml	Edgar Link	unprocessable
regn-20141231_lab.xml	Edgar Link	unprocessable
regn-20141231_pre.xml	Edgar Link	unprocessable
regn-ex_10101x12312014x10k.htm	Edgar Link	pending
regn-ex_10212x12312014x10k.htm	Edgar Link	pending
regn-ex_10252x12312014x10k.htm	Edgar Link	pending
regn-ex_10253x12312014x10k.htm	Edgar Link	pending
regn-ex_211x12312014x10k.htm	Edgar Link	pending
regn-ex_231x12312014x10k.htm	Edgar Link	pending
regn-ex_311x12312014x10k.htm	Edgar Link	pending
regn-ex_312x12312014x10k.htm	Edgar Link	pending
regn-ex_32x12312014x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2013 Q4 Form 10-K Financial Statement

#000153217615000008 Filed on February 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2013 Q4 Form 10-K Financial Statement

#000153217615000008 Filed on February 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn